Symphony Health’s New Enhanced Views Program Expands Evidence-Driven Insights

Enhanced panel provides expanded insights across multiple information assets and offers new insight to patient activity and the treatment journey

Phoenix, Arizona, UNITED STATES

CONSHOHOCKEN, Pa., April 03, 2018 (GLOBE NEWSWIRE) -- Symphony Health, a PRA Health Sciences company and a leading provider of data, cloud-based analytics and consulting solutions to life science companies and healthcare organizations, today announces the launch of the Enhanced Views program. This program encompasses a broad spectrum of expanded data assets and enhanced market measurement capabilities to provide improved visibility, understanding and insights of disease and treatments for biopharmaceutical brands.

As the need for broader and deeper analytic insights has increased, Symphony Health has significantly invested in acquiring new data assets and improving the functionality of the tools used to consume and analyze this information.  As a result of this initiative, the company has increased sample across supplier categories, and added new claims data assets in key therapeutic areas and across medical processes. The Enhanced Views program delivers an expanded sample that includes increased mail order supplier coverage, increased specialty pharmacy coverage, additional independent pharmacies in key geographies and entirely new offerings measuring the long-term care channel. In addition, the program provides increased granularity of managed care influences along with increased oncology claims, remittance claims, and integrated clinical content from electronic medical records integrated within Symphony Health’s IDV® (Integrated Dataverse).  

Symphony Health’s Enhanced Views panel leverages the power of the IDV® platform, the most comprehensive and interconnected source of healthcare data in the industry. Integration of data from multiple sources within IDV creates a consistent market view across prescriber, payer, and patient dimensions, and importantly reveals real-world behaviors which allows for better retail and non-retail tracking and measurement.   

“The need for more refined evidence-driven insights is only increasing as personalized medicine continues to show even more potential,” noted Jim Mahon, EVP, Product Management & Corporate Development. “With improved access to integrated health data, manufacturers can use evidence-based insights to provide better information to patients and providers based on near real-time data. These advances in analytics based on robust data solutions can yield novel insights impacting disease and treatment pathways.”

Beginning in May 2018, Symphony Health’s official national market measurement numbers will reflect the new enhanced panel with long term care data from the company’s national audit tool, PHAST®.

For more information, visit Symphony Health or contact us at

About Symphony Health:
Symphony Health is a leading provider of high-value data, analytics, and technology solutions for biopharmaceutical manufacturers, healthcare providers, and payers. The company helps clients understand disease incidence, prevalence, progression, treatment and influences along the patient and prescriber journeys by connecting and integrating a broad set of primary and secondary data, and providing health research, analytics and consulting expertise. Symphony Health derived data improves health management decisions, and helps clients drive revenue growth while providing critical insights on how to effectively adapt to the changing healthcare ecosystem. For more information, visit

About PRA Health Sciences:

PRA Health Sciences (NASDAQ:PRAH) is one of the world’s leading global contract research organizations, or CROs, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and over 15,800 employees worldwide. Since 2000, PRA has participated in approximately 3,700 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 75 drugs. To learn more about PRA, please visit

Media Contacts

Heather Varela                                                                                
Symphony Health
Director, Marketing Communications                                                                                                             
(602) 463-7838                                                                                  

Christine Rogers
PRA Health Sciences, Inc.
Director, Public Relations